Zymeworks to license ZW209 to Roche for $55 million upfront payment
Zymeworks signed a Collaboration and License Agreement with Roche on October 22, 2026, giving Roche exclusive worldwide rights to develop and commercialize its ZW209 DLL3-targeting trispecific T-cell engager. The deal includes a $55 million upfront payment and up to $718 million in milestones, and it takes effect only after U.S. Hart-Scott-Rodino clearance, while Roche can terminate at any time.
Key points
- Upfront non-refundable payment of $55 million, due after HSR Clearance
- Non-refundable $40 million milestone on initiation of the Phase Ib Trial, plus up to $718 million in other milestones
- Tiered high-single-digit to mid-teen royalties on annual net sales, with Zymeworks conducting the Phase Ia trial at Roche's expense
- Roche may terminate the agreement in its sole discretion at any time; Zymeworks' exclusivity restriction runs up to five years
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.